Estudos dos distúrbios da coagulação em pacientes portadores da Covid-19

Abstract

The severe acute respiratory syndrome 2 (SARS-CoV - 2), also known as COVID-19, responsible for the pandemic that occurred in the year 2020, was identified for the first time in Wuhan, capital of Hubei province, in China. COVID 19 is related to disorders of coagulation, a process that ensures the maintenance of blood hemostasis. This study deals with a literature review carried out between January 2020 and June 2021, using the SciELO, Virtual Health Library (VHL) and PubMed platforms. Hematological manifestations such as alterations in the D-dimer, fibrinogen and IL-6 can be found in the occurrence of infection by COVID-19. D-dimer is a good prognostic factor in these patients, although there is no consensus on its cutoff value in the literature. Regarding anticoagulant therapy, we still do not have well-established guidelines for its use. Regarding the use of Tocilizumab, a monoclonal antibody that competes for the IL-6 receptor, it seems to be well indicated in selected patients, as demonstrated by the RECOVERY multicenter study. Therefore, it is concluded that the infection by COVID-19 is still a challenge for all professionals who deal with the infected on a daily basis.